Eton Pharma closes $22.5M Increlex acquisition; expands credit facility

Eton Pharmaceuticals, Inc.

Acquired Increlex (mecasermin) from Ipsen for $22.5M at closing plus $8.7M inventory; $2.5M due on first and second anniversaries.
Credit facility with SWK expanded by $25.7M to $30M, maturity to 3 years, SOFR+6.75%; warrant for 289,736 shares at $5.32 issued.
Increlex is the only FDA/EMA approved treatment for severe primary IGF-1 deficiency in pediatric patients aged 2+.
U.S. available via AnovoRx specialty pharmacy; Eton to commercialize outside U.S. after 6-month transition.
Additional inventory purchase obligation up to EUR 15.0 million over 30 months; transaction financed by cash and credit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.